Join our Community
Support ToI and remove all ads
Learn more

ISRAEL AT WAR - DAY 425

Perrigo

Illustrative image of medication, drugs, prescription pills (Kubra Cavus; iStock by Getty Images)
From the WebMarch 1, 2021, 5:20 pm
Perrigo sells generics division for $1.55 billion to Altaris
Globes: The sale ends all activities of Perrigo in Israel and also raises the possibility that the American-Irish drugmaker might delist shares from the Tel Aviv Stock Exchange
Illustrative image of prescription drugs. (Hadas Parush/Flash90)
November 12, 2017, 12:07 pm
Drug company to pay out NIS 47.5m for causing depression and hair loss
Perrigo Israel sued by users of thyroid medicine Eltroxin after change in formula left hundreds with side effects
By Stuart Winer
A broker at the Tel Aviv Stock Exchange (photo credit: Moshe Shai/Flash90)
From the WebNovember 5, 2015, 12:41 am
Mylan lists in Tel Aviv in latest salvo in Perrigo battle
Bloomberg: An ongoing business battle took on an Israeli twist as two drug giants based abroad choose the TASE for their showdown
The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (Yonatan Sindel/Flash90)
April 27, 2015, 7:47 pm
Mylan rebuffs Teva again; calls bid low, insincere
Generic drug company rejects $40.1-billion takeover offer from Israeli pharmaceutical power for second time
By AFP
Illustrative photo of pharmaceutical pills. (Abed Rahim Khatib/Flash90)
From the WebAugust 15, 2014, 1:40 pm
Perrigo sees 2015 profit approaching $1 billion
Jewish Business News: The generic drug company’s fourth quarter results beat analysts’ estimates
An analyst checks the numbers on the Tel Aviv Stock Exchange (Photo credit Meir Partush/Flash90)
From the WebJuly 15, 2014, 5:55 pm
Israel stocks head to three-week high amid Perrigo deal report
Businessweek: As the missiles fly outside, traders inside the Tel Aviv Stock Exchange are trading up shares
pharmaceuticals (Photo credit: Flash90)
From the WebJanuary 12, 2014, 10:24 am
Perrigo at record on M&A outlook amid tax rate
Bloomberg: Shares of an US pharma giant are up after the acquisition of an Israeli drug maker
Load More
Sign in or Register
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.